268 related articles for article (PubMed ID: 26607486)
1. European Union-28: An annualised cost-of-illness model for venous thromboembolism.
Barco S; Woersching AL; Spyropoulos AC; Piovella F; Mahan CE
Thromb Haemost; 2016 Apr; 115(4):800-8. PubMed ID: 26607486
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.
Mahan CE; Borrego ME; Woersching AL; Federici R; Downey R; Tiongson J; Bieniarz MC; Cavanaugh BJ; Spyropoulos AC
Thromb Haemost; 2012 Aug; 108(2):291-302. PubMed ID: 22739656
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study.
Henderson RH; French D; Maughan T; Adams R; Allemani C; Minicozzi P; Coleman MP; McFerran E; Sullivan R; Lawler M
Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):709-722. PubMed ID: 34329626
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model.
Marcellusi A; Viti R; Capone A; Mennini FS
Eur Rev Med Pharmacol Sci; 2015; 19(9):1610-20. PubMed ID: 26004601
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden of Bladder Cancer Across the European Union.
Leal J; Luengo-Fernandez R; Sullivan R; Witjes JA
Eur Urol; 2016 Mar; 69(3):438-47. PubMed ID: 26508308
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.
Grosse SD; Nelson RE; Nyarko KA; Richardson LC; Raskob GE
Thromb Res; 2016 Jan; 137():3-10. PubMed ID: 26654719
[TBL] [Abstract][Full Text] [Related]
7. The economic costs of overactive bladder in Germany.
Klotz T; Brüggenjürgen B; Burkart M; Resch A
Eur Urol; 2007 Jun; 51(6):1654-62; discussion 1662-3. PubMed ID: 17161521
[TBL] [Abstract][Full Text] [Related]
8. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event.
Mahan CE; Holdsworth MT; Welch SM; Borrego M; Spyropoulos AC
Thromb Haemost; 2011 Sep; 106(3):405-15. PubMed ID: 21833446
[TBL] [Abstract][Full Text] [Related]
9. Cost of disorders of the brain in Europe 2010.
Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jönsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen HC; Stovner LJ; Vallat JM; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen HU; Jönsson B; Olesen J;
Eur Neuropsychopharmacol; 2011 Oct; 21(10):718-79. PubMed ID: 21924589
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of cancer across the European Union: a population-based cost analysis.
Luengo-Fernandez R; Leal J; Gray A; Sullivan R
Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
[TBL] [Abstract][Full Text] [Related]
11. Estimating the cost of epilepsy in Europe: a review with economic modeling.
Pugliatti M; Beghi E; Forsgren L; Ekman M; Sobocki P
Epilepsia; 2007 Dec; 48(12):2224-33. PubMed ID: 18088267
[TBL] [Abstract][Full Text] [Related]
12. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
13. Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.
Weidlich D; Andersson FL; Oelke M; Drake MJ; Jonasson AF; Guest JF
Eur J Health Econ; 2017 Jul; 18(6):761-771. PubMed ID: 27678109
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of venous thromboembolism: a systematic review.
Ruppert A; Steinle T; Lees M
J Med Econ; 2011; 14(1):65-74. PubMed ID: 21222564
[TBL] [Abstract][Full Text] [Related]
15. Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in the European Union.
Bellanger M; Demeneix B; Grandjean P; Zoeller RT; Trasande L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1256-66. PubMed ID: 25742515
[TBL] [Abstract][Full Text] [Related]
16. Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.
Mennini FS; Marcellusi A; Gitto L; Iannone F
Clin Drug Investig; 2017 Apr; 37(4):375-386. PubMed ID: 28074337
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of malignant blood disorders across Europe: a population-based cost analysis.
Burns R; Leal J; Sullivan R; Luengo-Fernandez R
Lancet Haematol; 2016 Aug; 3(8):e362-70. PubMed ID: 27476787
[TBL] [Abstract][Full Text] [Related]
18. Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association
Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
[TBL] [Abstract][Full Text] [Related]
19. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of non-malignant blood disorders across Europe: a population-based cost study.
Luengo-Fernandez R; Burns R; Leal J
Lancet Haematol; 2016 Aug; 3(8):e371-8. PubMed ID: 27476788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
